<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677153</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00265240</org_study_id>
    <nct_id>NCT04677153</nct_id>
  </id_info>
  <brief_title>Rapid HCV Treatment Access for Persons Who Use Drugs</brief_title>
  <acronym>RAPID-HCV</acronym>
  <official_title>Rapid HCV Test and Treat to Increase HCV Treatment Uptake Among People Who Use Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to compare two strategies to deliver HCV treatment to persons with&#xD;
      hepatitis C virus (HCV) who also use drugs and are participating in an outpatient opioid&#xD;
      treatment program (OTP). Participants will be randomized into one of two treatment groups:&#xD;
&#xD;
        1. Test and treat plus peer-mentors: This treatment group will be offered 8 weeks of&#xD;
           glecaprevir/pibrentasvir (an FDA approved HCV treatment) within days of HCV diagnosis at&#xD;
           the OTP. Participants in this group will receive treatment adherence support from a&#xD;
           peer-mentor who is someone who has been cured of HCV infection.&#xD;
&#xD;
        2. Standard of care HCV treatment referral: This treatment group will be referred to an&#xD;
           offsite HCV treatment location. This is the usual care for anyone who tests positive for&#xD;
           HCV at the OTP who is not participating in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Who Initiate HCV Therapy</measure>
    <time_frame>Within 12 weeks of randomization</time_frame>
    <description>Proportion of participants who start HCV treatment in each arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCV Treatment Completion</measure>
    <time_frame>At expected end of treatment date, up to 20 weeks</time_frame>
    <description>Proportion of participants who start HCV treatment and subsequently complete treatment (take more than 90% of prescribed treatment course).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response (SVR) Following Treatment by Intervention Group</measure>
    <time_frame>Post-treatment week 12</time_frame>
    <description>Proportion of participants in each arm who achieved SVR, defined as HCV RNA not detected at 12 weeks after completion of the HCV treatment regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to HCV Treatment Initiation</measure>
    <time_frame>From positive HCV antibody result to initiation of treatment, up to 36 weeks</time_frame>
    <description>Time to HCV Treatment Initiation in weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hepatitis C Virus Infection, Response to Therapy of</condition>
  <arm_group>
    <arm_group_label>Test and Treat plus Peer Mentors Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants offered 8 weeks of glecaprevir/pibrentasvir (GLE/PIB) at OTP plus peer support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Referral Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants referred to offsite (non-OTP) location for HCV treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test and treat plus peer mentors</intervention_name>
    <description>Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.</description>
    <arm_group_label>Test and Treat plus Peer Mentors Intervention Arm</arm_group_label>
    <other_name>On-site treatment with peer support HCV treatment implementation strategy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Participants are referred to another location for HCV treatment.</description>
    <arm_group_label>Standard of Care Referral Arm</arm_group_label>
    <other_name>Standard of care referral HCV treatment implementation strategy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability and willingness of participant to provide written informed consent&#xD;
&#xD;
          -  Men and women age ≥18 to ≤70 years at study entry&#xD;
&#xD;
          -  HCV antibody positive&#xD;
&#xD;
          -  HCV treatment naïve (no prior treatment with an approved or investigational anti HCV&#xD;
             medication)&#xD;
&#xD;
          -  Negative pregnancy test at screening or at the day of treatment initiation (females of&#xD;
             childbearing potential only)&#xD;
&#xD;
          -  If co-infection with Human Immunodeficiency Virus (HIV) is documented, the subject&#xD;
             must be anti-retroviral treatment (ART) naïve with CD4 T cell count &gt;500 cells/mm3 OR&#xD;
             on a stable ART regimen (containing only permissible ART - Raltegravir; dolutegravir;&#xD;
             Rilpivirine; Elvitegravir/cobicistat; Tenofovir disoproxil fumarate; Tenofovir&#xD;
             alafenamide; Emtricitabine; Lamivudine and/or Abacavir, bictegravir)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding, or considering becoming pregnant during the&#xD;
             study and for 30 days after the last dose of study drug&#xD;
&#xD;
          -  Known allergy/sensitivity or any hypersensitivity to components of study drugs or&#xD;
             their formulation&#xD;
&#xD;
          -  Current or history of decompensated liver disease (including but not limited to&#xD;
             encephalopathy, variceal bleeding, or ascites) prior to study entry&#xD;
&#xD;
          -  History of hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Any history of active Hepatitis B or positive HBsAg test&#xD;
&#xD;
          -  Platelet count &lt; 150,000/mm3&#xD;
&#xD;
          -  HCV RNA undetectable&#xD;
&#xD;
          -  History of clinically significant abnormalities or co-morbidities that make the&#xD;
             subject an unsuitable candidate for this study, in the opinion of the investigator.&#xD;
&#xD;
          -  Women of childbearing potential that are not practicing at least one specified method&#xD;
             of birth control that is effective from Study Day 1 through at least 30 days after the&#xD;
             last dose of study drug.&#xD;
&#xD;
          -  Subject is currently taking any of the following prohibited medications: red yeast&#xD;
             rice (monacolin K), St. John's Wort, carbamazepine, dabigatran, efavirenz, phenytoin,&#xD;
             pentobarbital, phenobarbital, primidone, rifabutin, rifampin.&#xD;
&#xD;
          -  Subject is not able or willing to safely discontinue the prohibited medications or&#xD;
             supplements listed below at least 14 days prior to the first dose of GLE/PIB: some&#xD;
             HMG-CoA reductase inhibitors, astemizole, cisapride, terfenadine, ethinyl estradiol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oluwaseun Falade-Nwulia, MBBS, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oluwaseun Falade-Nwulia, MBBS, MPH</last_name>
    <phone>4422871964</phone>
    <email>ofalade1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Sulkowski, MD</last_name>
    <phone>410-955-7538</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ricardo Franco, MD</last_name>
      <email>rfranco@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Ricardo Franco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Price, MD, PhD</last_name>
      <email>Jennifer.Price@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Price, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oluwaseun Falade-Nwulia, MBBS, MPH</last_name>
      <email>ofalade1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Oluwaseun Falade-Nwulia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jordan Feld, MD, MPH</last_name>
      <email>Jordan.Feld@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Jordan Feld, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

